Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 6/20 | 0.36 |
| ▸ | CA2 | P00918 | 6/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5490945 | 1.00 | MEN1 (0.43) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL18262806 | 0.96 | TDP1 (0.44) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL1795152 | 0.96 | TDP1 (0.44) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL12514747 | 0.96 | TDP1 (0.44) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL20122294 | 0.94 | TDP1 (0.47) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL12155283 | 0.94 | TDP1 (0.47) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL20191171 | 0.94 | TDP1 (0.47) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL16322976 | 0.91 | MEN1 (0.39) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL17234179 | 0.91 | MEN1 (0.39) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL1793511 | 0.91 | MEN1 (0.39) | MEN1GAAKMT2ATDP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305198-A1 | CATIONIC LIPIDS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURG (GB) | 2010-12-02 | — | — | US | disclosed |
| EP-2212279-A1 | CATIONIC LIPIDS | The University Court Of The University of Edinburgh (GB) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009050483-A1 | CATIONIC LIPIDS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2009-04-23 | — | — | WO | disclosed |
| US-7163921-B1 | Peptide derivatives and medicinal compositions | NIPPON SHINYAKU CO., LTD. (JP) | 2007-01-16 | — | — | US | disclosed |
| EP-1275657-A1 | PEPTIDE DERIVATIVES AND MEDICINAL COMPOSITIONS | Nippon Shinyaku Co., Ltd. (JP) | 2003-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305198-A1 | CATIONIC LIPIDS | CETP, LIPA, ABHD16A | MEN1 1595/4885GAA 1393/4885KMT2A 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.